007570 — Ilyang Pharmaceutical Share Price
Last trade - 00:00- KR₩125bn
- KR₩217bn
- KR₩272bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 0.55 | ||
| Price to Free Cashflow | 5.39 | ||
| Price to Sales | 0.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.61% | ||
| Return on Equity | 6.91% | ||
| Operating Margin | -4.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 242,511.45 | 247,772.6 | 266,669 | 268,677.53 | 272,422.21 | n/a | n/a | -4.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.05 | +37.28 | -55.73 | +5.97 | -24.35 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ilyang Pharmaceutical Co Ltd is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company mainly provides prescription drugs such as anti-ulcer agents and anti-inflammatory drugs, over-the-counter products such as tonics, as well as active pharmaceutical ingredients and health supplements. In addition, the Company is involved in the supply of software.
Directors
- Dong Yeon Kim PRE (62)
- Gyu Yeong Choi DRC (55)
- Yu Seok Jung DRC (36)
- Myeong Sik Bae NID (65)
- Seung Nam Joo NID (69)
- Jae Yeong Woo NID (67)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 1st, 1946
- Public Since
- August 28th, 1974
- No. of Employees
- 636
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 17,924,965
- Address
- 110, Hagal-ro, Giheung-gu, YONGIN, 17096
- Web
- https://www.ilyang.co.kr/
- Phone
- +82 312817851
- Auditors
- KPMG Samjong Accounting Corp
Latest News for 007570
Upcoming Events for 007570
Q3 2026 Ilyang Pharmaceutical Co Ltd Earnings Release
Q4 2026 Ilyang Pharmaceutical Co Ltd Earnings Release
Ilyang Pharmaceutical Co Ltd Annual Shareholders Meeting
Similar to 007570
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
As of Today at 21:16 UTC, shares in Ilyang Pharmaceutical are trading at KR₩7,000. This share price information is delayed by 15 minutes.
Shares in Ilyang Pharmaceutical last closed at KR₩7,000 and the price had moved by -46.36% over the past 365 days. In terms of relative price strength the Ilyang Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -60.17% over the past year.
The overall consensus recommendation for Ilyang Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Ilyang Pharmaceutical dividend yield is 2.21% based on the trailing twelve month period.
Last year, Ilyang Pharmaceutical paid a total dividend of KR₩155, and it currently has a trailing dividend yield of 2.21%. We do not have any data on when Ilyang Pharmaceutical is to next pay dividends.
We do not have data on when Ilyang Pharmaceutical is to next pay dividends. The historic dividend yield on Ilyang Pharmaceutical shares is currently 2.21%.
To buy shares in Ilyang Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩7,000, shares in Ilyang Pharmaceutical had a market capitalisation of KR₩125bn.
Here are the trading details for Ilyang Pharmaceutical:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 007570
Based on an overall assessment of its quality, value and momentum Ilyang Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ilyang Pharmaceutical is KR₩38,000. That is 442.86% above the last closing price of KR₩7,000.
Analysts covering Ilyang Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ilyang Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -41%.
As of the last closing price of KR₩7,000, shares in Ilyang Pharmaceutical were trading -31.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ilyang Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩7,000.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ilyang Pharmaceutical's management team is headed by:
- Dong Yeon Kim - PRE
- Gyu Yeong Choi - DRC
- Yu Seok Jung - DRC
- Myeong Sik Bae - NID
- Seung Nam Joo - NID
- Jae Yeong Woo - NID